Abstract 57P
Background
The formation of distant metastases is the deadliest phase of cancer progression. Nevertheless, it is a very inefficient process. Chances of a tumor cell surviving the metastatic process depend on its ability to communicate with the surrounding environment. We hypothesize that metastasis organotropism can be partially explained by the intercellular communication established between cancer cells and other cells in the organ microenvironment.
Methods
Network biology tools are well suited for studying complex diseases such as cancer. Using this computational approach we looked at the complex interplay between proteins and pathways affected in metastasis and identified new metastasis-associated proteins. We built networks of tissue-specific intercellular protein-protein interactions between pairs of primary tumor location and metastasis tissues. Using these networks we identified interactions significantly more frequent in organotropism tissue pairs (primary tumor and metastasis organ) that potentially influence the success of metastasis in specific organs.
Results
Overall, we identified 607 proteins involved in 1095 metastasis-associated interactions. Of these, 881 interactions were positively associated with metastasis, meaning that these interactions occur more frequently in organotropism tissue-pairs than in other tissue pairs. Of the 607 proteins found, 222 are already targeted by known drugs and 53 are targeted by drugs that are not used in cancer treatment.
Conclusions
Cell-cell communication is of paramount importance for the development of metastasis. Experimental studies of the non-oncological drugs targeting the 53 identified proteins are needed to select the most promising candidates to test in drug repurposing clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09